Despite the fact that only a small proportion of iCCA patients are affected by dysregulation in NF-κB signaling, it is still crucial to better understand the complexity of NF-κB regulation in these patients, as it might influence future (immunotherapeutic) treatment approaches. This evidence concerns the gene NFKB1 and infantile convulsions and choreoathetosis.